Although ARAF mutations only constitute ~1.4% of lung cancers, with the ARAF p.S214C mutation occurring in ~0.03% of lung adenocarcinoma cases [8,32], our findings revealed the therapeutic potential of sorafenib in a distinct subgroup of patients. Here, ARAF is linked to lung adenocarcinoma.